SEC jumps in­to the Fi­bro­Gen fi­as­co with a sub­poe­na, prob­ing car­dio da­ta ma­nip­u­la­tion

As­traZeneca part­ner Fi­bro­Gen stunned an­a­lysts last April with the news that the safe­ty da­ta around their ane­mia drug rox­adu­s­tat had been doc­tored up to make cer­tain safe­ty is­sues dis­ap­pear. And now we know that the SEC has de­cid­ed to get in­to the act.

From their 10-K yes­ter­day:

In the fourth quar­ter of 2021, Fi­bro­Gen re­ceived a sub­poe­na from the SEC re­quest­ing doc­u­ments re­lat­ed to rox­adu­s­tat’s pooled car­dio­vas­cu­lar safe­ty da­ta. We have been ful­ly co­op­er­at­ing with the SEC’s in­ves­ti­ga­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER